120 related articles for article (PubMed ID: 38643510)
1. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R; Alsina L; Azar A; Bertrand Y; Bolyard AA; Dale DC; Deyà-Martinez À; Dickerson KE; Ezra N; Hasle H; Kang HJ; Kiani-Alikhan S; Kuijpers TW; Kulagin A; Langguth D; Levin C; Neth O; Olbrich P; Peake J; Rodina Y; Rutten CE; Shcherbina A; Tarrant TK; Vossen MG; Wysocki CA; Belschner A; Bridger GJ; Chen K; Dubuc S; Hu Y; Jiang H; Li S; MacLeod R; Stewart M; Taveras AG; Yan T; Donadieu J
Blood; 2024 Apr; ():. PubMed ID: 38643510
[TBL] [Abstract][Full Text] [Related]
2. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4
Zmajkovicova K; Pawar S; Maier-Munsa S; Maierhofer B; Wiest I; Skerlj R; Taveras AG; Badarau A
Genes Immun; 2022 Sep; 23(6):196-204. PubMed ID: 36089616
[TBL] [Abstract][Full Text] [Related]
4. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. A Novel Transmembrane CXCR4 Variant That Expands the WHIM Genotype-Phenotype Paradigm.
Zmajkovicova K; Pawar S; Sharapova SO; Geier CB; Wiest I; Nguyen C; Monticelli H; Maier-Munsa S; Chen K; Sleasman JW; Aleshkevich S; Polyakova E; Sakovich I; Warnatz K; Grimbacher B; Proietti M; Sondheimer N; Ujhazi B; Gordon S; Ellison M; Yilmaz M; Walter JE; Badarau A; Taveras AG; Neff JL; Bledsoe JR; Tarrant TK
Blood Adv; 2024 May; ():. PubMed ID: 38768429
[TBL] [Abstract][Full Text] [Related]
8. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial.
Zhang Y; Yan B; Zhu Z; Wang X; Song X; Zhu D; Ma T; Zhang Y; Meng C; Wang G; Wang C; Zhang L
EClinicalMedicine; 2024 Mar; 69():102467. PubMed ID: 38356731
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Tehlirian C; Peeva E; Kieras E; Scaramozza M; Roberts ES; Singh RSP; Pradhan V; Banerjee A; Garcet S; Xi L; Gale JD; Vincent MS; Krueger J
Lancet Rheumatol; 2021 Mar; 3(3):e204-e213. PubMed ID: 38279383
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Hematologic Effects of Endotoxin in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome Model Mice.
Majumdar S; Gao JL; Pontejo SM; Balabanian K; Bachelerie F; Murphy PM
Immunohorizons; 2022 Jul; 6(7):543-558. PubMed ID: 35882421
[TBL] [Abstract][Full Text] [Related]
16. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
17. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
[TBL] [Abstract][Full Text] [Related]
18. Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI; Wang Y; Pierce RH; Campbell JS; Yushak M; Milhem M; Ross M; Niland K; Arbeit RD; Parasuraman S; Bickley K; Yeung CC; Aicher LD; Smythe KS; Gan L
Cancer Res Commun; 2022 Aug; 2(8):904-913. PubMed ID: 36923305
[TBL] [Abstract][Full Text] [Related]
19. Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.
Blood; 2023 Jun; 141(26):3232. PubMed ID: 37383001
[No Abstract] [Full Text] [Related]
20. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
